So, Kroger (KR) shares are up a bit. Why? Because the grocery chain is now stocking a particular kind of weight-loss pen. It's the kind of news that makes you go, "Huh, okay," and then you realize there's a whole story about pharmacy strategy, stock charts, and ETF mechanics behind it.
The company confirmed it's launching the Zepbound KwikPen at participating Kroger pharmacies. This is a multi-dose delivery option for Eli Lilly and Company's (LLY) GLP-1 therapy, and it's available for self-pay patients. In simpler terms: if you want this specific form of a popular weight management drug and you're paying out of pocket, you can now potentially get it at Kroger.
Kroger's stock performance is moving with the overall market, with the consumer discretionary sector gaining 0.21% on the day.
What the Charts Are Saying
Let's talk numbers. The stock is currently trading 7.2% above its 20-day simple moving average and 14.5% above its 100-day simple moving average. That shows some decent short-term momentum.
Over the past year, shares are up 13.44% and are sitting closer to their 52-week highs than their lows. The RSI (Relative Strength Index) is at 66.72, which is considered neutral territory—it's getting warm but isn't in the "overbought" red zone yet. The MACD, another momentum indicator, is showing a bullish signal with a value of 1.9724, above its signal line at 1.5882. The takeaway? The bullish trend is still there, but the stock isn't screamingly cheap.
- Key Resistance: $76.50
- Key Support: $61.00
Here's the interesting bit: Kroger is actually underperforming its sector today, with a daily gain of 0.13% compared to the Consumer Discretionary sector's 0.21% increase. The sector itself ranks 8 out of 11, which is mid-tier, and it's down 5.15% over the past month. So, it's a tough environment for these types of stocks right now.
Despite that, moves like adding the Zepbound KwikPen are part of Kroger's play to bolster its position. Expanding access to healthcare stuff—especially the kind people are actively seeking out—fits with changing what customers want and could give Kroger an edge. This launch highlights the company's focus on making healthcare more accessible, which is a smart way to enhance its service offerings and stand out in the crowded retail world.
What the Analysts Think and What's Next
Kroger is expected to provide its next financial update on June 22, 2026 (that's an estimate, so mark it in pencil).
- EPS Estimate: $1.59 (Up from $1.49)
- Revenue Estimate: $45.39 Billion (Up from $45.12 Billion)
- Valuation: P/E of 48.7x (That indicates a premium valuation)
The analyst consensus is a Buy rating with an average price target of $74.07. Recently, a few analysts have been tweaking their numbers:
- Evercore ISI Group: Outperform (Raises Target to $83.00) (Mar. 9)
- Citigroup: Neutral (Raises Target to $71.00) (Mar. 9)
- Roth Capital: Buy (Raises Target to $78.00) (Mar. 6)
